Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Erenumab in Episodic Migraine Prevention
NCT01952574Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2013
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of erenumab in migraine (4 arms), sponsored by Amgen. Primary endpoints: Change From Baseline in Monthly Migraine Days at Week 12 and CHU Substudy: Number of Participants Who Self-administered a Full Dose, Partial Dose, or No Dose of Erenumab at 8 weeks. Started Aug 2013; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT01952574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01952574.